BELBUCA has been proven to reduce severe and persistent pain versus placebo*
In people previously taking commonly prescribed opioids like hydrocodone, tramadol, oxycodone, and morphine
BELBUCA has been proven to reduce severe and persistent pain versus placebo*
In people previously taking commonly prescribed opioids like hydrocodone, tramadol, oxycodone, and morphine
BELBUCA has 7 dosage strengths and is taken 2 times a day (every 12 hours)
Multiple dosage strengths may help you and your healthcare provider find the dose that provides the relief you need from severe and persistent pain. Maximum dose is 900 mcg every 12 hours
Be patient, and give your body time! You may experience a change in symptoms. It may take time and a few adjustments to find your optimal dose. Be sure to continue to talk with your healthcare provider about how you are feeling and how well your pain is being managed. Once you are effectively managed on BELBUCA, you may be able to reduce or eliminate the amount of rescue medicine needed to manage your severe and persistent pain.
Get emergency help or call 911 right away if you take too much BELBUCA (overdose). When you first start taking BELBUCA, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Ask your healthcare provider about medicines like naloxone or nalmefene that can be used in an emergency to reverse an opioid overdose.
The possible side effects of BELBUCA include nausea, constipation, headache, vomiting, dizziness, and sleepiness.†
Call your healthcare provider if you have any of these symptoms and they are severe
These are not all the possible side effects of BELBUCA. Call your healthcare provider for medical advice about side effects.
†These are the most commonly reported side effects by patients participating in clinical studies comparing BELBUCA with placebo (sugar pill). Individual results may vary.
BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing BELBUCA, and monitor regularly for these behaviors and conditions.
Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.
Accidental exposure to even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine.
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.
These are not all the possible side effects of BELBUCA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.
Please see full Prescribing Information, including Boxed Warning on Addiction, Abuse, and Misuse, and other serious risks, and Medication Guide, or speak to your healthcare provider if you have questions about BELBUCA.